Not for release, publication or distribution in the United States, Canada, Australia or Japan
This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of Bavarian Nordic A/S (the "Securities") in the United States or in any other jurisdiction. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the Securities has not registered, and does not intend to register, any portion of the Offering in the United States or in any jurisdiction outside Denmark and the United Kingdom, and does not intend to conduct a public offering of the Securities in the United States or in any other jurisdiction outside Denmark and the United Kingdom. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.
This announcement is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors, as that term is defined in the Prospectus Directive, that are also (i) "investment professionals" falling within Article 19(5) of the Financial Service and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) "high net worth entities" and other persons to whom it may lawfully be communicated, falling within the meaning of Article 49(2)(a) to (d) of the Order (all such persons being "relevant persons"). The securities of Bavarian Nordic A/S (the "Securities") are only available to relevant persons and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its content.
Kvistgaard, Denmark, May 23, 2011 - Pursuant to Section § 28a of the Danish Act on Securities Trading, Bavarian Nordic A/S reports the following transactions of shares and related securities of Bavarian Nordic A/S by persons holding managerial responsibilities and/or persons/companies closely associated with such.
|
Name |
Erik G. Hansen |
|
Reason for transaction |
Member of the Board of Directors of Bavarian Nordic A/S |
|
Issuer |
Bavarian Nordic A/S |
|
ID code/ISIN |
DK0060307932 |
|
Description |
Subscription rights |
|
Transaction |
Purchase |
|
Trading date |
18 May 2011 |
|
Market |
NASDAQ OMX Copenhagen |
|
Number |
3,500 |
|
Market value (DKK) |
42,735.00 |
|
Name |
Erik G. Hansen |
|
Reason for transaction |
Member of the Board of Directors of Bavarian Nordic A/S |
|
Issuer |
Bavarian Nordic A/S |
|
ID code/ISIN |
DK0060307932 |
|
Description |
Subscription rights |
|
Transaction |
Purchase |
|
Trading date |
19 May 2011 |
|
Market |
NASDAQ OMX Copenhagen |
|
Number |
3,500 |
|
Market value (DKK) |
32,375.00 |
|
Name |
Sirius Holding ApS |
|
Reason for transaction |
Closely related to Erik G. Hansen, member of the Board of Directors of Bavarian Nordic A/S |
|
Issuer |
Bavarian Nordic A/S |
|
ID code/ISIN |
DK0060307932 |
|
Description |
Subscription rights |
|
Transaction |
Purchase |
|
Trading date |
19 May 2011 |
|
Market |
NASDAQ OMX Copenhagen |
|
Number |
5,000 |
|
Market value (DKK) |
50,000.00 |
|
Name |
Qvinta Invest ApS |
|
Reason for transaction |
Closely related to Erik G. Hansen, member of the Board of Directors of Bavarian Nordic A/S |
|
Issuer |
Bavarian Nordic A/S |
|
ID code/ISIN |
DK0060307932 |
|
Description |
Subscription rights |
|
Transaction |
Purchase |
|
Trading date |
19 May 2011 |
|
Market |
NASDAQ OMX Copenhagen |
|
Number |
6,000 |
|
Market value (DKK) |
54,000.00 |
Asger Aamund
Chairman of the Board
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's clinical pipeline targets cancer and infectious diseases, and includes seven development programmes. Two programmes are under preparation for Phase III: PROSTVAC®, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
PROSTVAC® is a registered trademark in the U.S.
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
